Matrix metalloproteinase activity stimulates N-cadherin shedding and the soluble N-cadherin ectodomain promotes classical microglial activation

Katherine Conant 1*, Stefano Daniele 1†, P. Lorenzo Bozzelli 1†, Tsion Abdi 1, Amanda Edwards 1, Arek Szklarczyk 2, India Olchefske 1, David Ottenheimer 1 and Kathleen Maguire-Zeiss 1*

Abstract

Background: Matrix metalloproteinases (MMPs) are a family of enzymes that are typically released from intracellular stores to act on specific extracellular substrates. MMP expression and activity can be increased in a neuronal activity-dependent manner, and further increased in response to tissue injury. MMP substrates include cell adhesion molecules (CAMs) that are abundantly expressed in the brain and well positioned for membrane proximal cleavage. Importantly, CAM integrity is important to synaptic structure and axon-myelin interactions, and shed ectodomains may themselves influence cellular function.

Methods: In the present study, we have examined proteolysis of N-cadherin (N-cdh) by MMP-7, a family member that has been implicated in disorders including HIV dementia, multiple sclerosis, and major depression. With in vitro digest assays, we tested N-cdh cleavage by increasing concentrations of recombinant enzyme. We also tested MMP-7 for its potential to stimulate N-cdh shedding from cultured neural cells. Since select CAM ectodomains may interact with cell surface receptors that are expressed on microglial cells, we subsequently tested the N-cdh ectodomain for its ability to stimulate activation of this cell type as determined by nuclear translocation of NF-κB, Iba-1 expression, and TNF-α release.

Results: We observed that soluble N-cdh increased Iba-1 levels in microglial lysates, and also increased microglial release of the cytokine TNF-α. Effects were associated with increased NF-κB immunoreactivity in microglial nuclei and diminished by an inhibitor of the toll-like receptor adaptor protein, MyD88.

Conclusions: Together, these in vitro results suggest that soluble N-cdh may represent a novel effector of microglial activation, and that disorders with increased MMP levels may stimulate a cycle in which the products of excess proteolysis further exacerbate microglial-mediated tissue injury. Additional in vivo studies are warranted to address this issue.

Keywords: Matrix metalloproteinase, MMP, Toll-like receptor, TLR, Tumor necrosis factor, TNF, MyD88, Microglia
Background
Matrix metalloproteinase (MMP)-dependent proteolysis is increasingly recognized as an important effector of physiological plasticity, and learning and memory in particular [1]. However, since MMP activity can be dramatically upregulated with CNS injury, the potential for excessive enzyme activity to contribute to tissue injury must be considered. This latter possibility is supported by numerous in vivo studies in which broad-spectrum MMP inhibitors reduce brain injury in response to ischemia, viral infection, inflammatory stimuli, genetic disorders such as fragile X syndrome, and neurotoxicant exposure [2–4].

In terms of the mechanisms by which MMPs influence tissue injury, many studies have focused on their potential to influence blood brain barrier (BBB) permeability. Indeed, MMPs can cleave collagens that are critical components of the BBB [5–7]. MMPs can also influence BBB permeability in mouse models of ischemia and inflammation [8, 9]. It should be noted; however, that excess proteolysis of non-BBB targets might also contribute to MMP-dependent tissue injury.

Transmembrane cell adhesion molecules (CAMs) represent an important class of MMP substrates [1, 10]. CAMs are highly expressed on neurons and glial cells, and these molecules are well positioned to be targeted by MMPs following enzyme release from intracellular stores. CAM integrity may be critical to physiological synaptic plasticity, axon-myelin interactions, and reactive synaptogenesis [11–13]. Reduced CAM integrity has been linked to a reduction in synapse formation during the regenerative phase that follows brain injury [13]. In addition, and the focus of studies pursued herein, CAM fragments may also represent potent bioactive molecules [10, 14].

MMP-dependent CAM cleavage typically occurs proximal to the transmembrane domain, to release the major portion of the extracellular domain [15, 16]. The shed N-terminal fragment (NTF) is often relatively stable, in that elevated levels of shed NTFs can be detected in cerebrospinal fluid samples from patients with CNS injury and/or inflammation [17, 18]. CAM fragments could thus represent a class of damage-associated molecular patterns (DAMPs) [19, 20].

Receptors for DAMPs include toll-like receptors (TLRs). These receptors are highly expressed on the microglia, resident innate immune cells of the brain, and TLRs are known to engage extracellular matrix protein fragments that have homology to CAM ectodomain regions. Moreover, the existence of cleavage-generated TLR ligands is not without precedent. For example, in Drosophila, extracellular proteolysis generates Spatzle, which then acts as a ligand for a TLR-analogous immune and pattern recognition receptor [20–22].

With respect to CNS inflammation and injury, TLR signaling has been shown to stimulate microglial release of neurotoxic molecules including the pro-inflammatory cytokine tumor necrosis factor-α (TNF-α). TLR agonists have also been linked to inflammasome activation [23, 24]. TLR expression may be increased in the inflamed CNS [25], and TLR signaling through MyD88 may be critical to expression of select disease states. It is therefore not surprising that innate immunity and TLR activation, in particular, are thought to play an important role in the murine model of multiple sclerosis, a prototypic inflammatory condition [25]. Cells of the innate immune system, including the microglia, stimulate myelin reactive T cells, and depletion of macrophages or microglia leads to a marked attenuation of experimental autoimmune encephalomyelitis (EAE) despite the adequate T cell sensitization [26, 27]. In addition, recent studies have linked microglial activation to cortical or hippocampal injury [28, 29]. Microglial activation is also observed in HIV dementia and is thought to contribute to disease progression [30].

In the present study, we investigate shedding of N-cdh, a CAM that is relatively abundant in the CNS, using an in vitro digest system and a cell culture model. In addition, using a variety of in vitro approaches and primary murine microglial cell cultures, we investigate soluble N-cdh for its potential to stimulate specific correlates of classical microglial activation.

Methods
Reagents
Recombinant mouse N-cdh was purchased from R & D Systems (Minneapolis, MN; 6626-NC) and reconstituted in sterile phosphate buffered saline (PBS) prior to use. This construct contains the soluble ectodomain (Met1-Ala724), as well as a linker (IEGRMDP) and Glu98-Lys330 of mouse IgG2A. Recombinant protein used was from a lot that was tested for endotoxin, which was measured at 0.000648 EU per microgram protein. Recombinant active MMP-2 and MMP-7 were purchased from EMD Biosciences, Inc. (Billerica, MA), as was the MMP inhibitor GM-6001. ADAM-10 was purchased from R & D Systems (Minneapolis, MN) and reconstituted in sterile phosphate buffered saline (PBS) prior to use. Aliquots were stored at −80 °C. The RGDS peptide was purchased from Tocris Bioscience (Bristol, UK; 91037-65-9) and reconstituted in sterile PBS. Normal mouse IgG was purchased from Santa Cruz Biotechnology, Inc (Dallas, TX; sc-2025). Primary antibodies: to the C-terminal region of the p65 subunit of NF-κB were purchased from Abcam (anti-NF-κB p65 rabbit polyclonal (ab31481); Cambridge, MA); to the Iba-1 were purchased from Wako Chemical USA, Inc. (anti-Iba1 rabbit polyclonal (016-20001); Richmond, VA); and to the GAPDH were purchased from EMD Millipore (anti-GAPDH mouse monoclonal IgG1 (MAB374); Billerica, MA). For immunocytochemistry, Alexa Fluor® secondary antibodies were purchased from Molecular Probes/
Thermo Fisher Scientific (Waltham MA). For western blot analyses, horseradish peroxidase-conjugated secondary antibodies were purchased from EMD Millipore (goat anti-mouse-HRP, AP130P) and EMD Millipore (goat anti-rabbit-HRP, AP132P). The nuclear counterstain, DAPI, was purchased from Thermofisher Scientific (62247). Lymphopanned MyD88 inhibitor peptide and its control peptide were from Imgenex (San Diego, CA) and reconstituted in sterile PBS to a working concentration of 5 mM. Antibody to N-cdh was purchased from Millipore (Billerica, MA).

In vitro digests
Unless otherwise noted, in vitro digests were performed as previously described using 2.5 μg recombinant N-cdh and 0.5 μg recombinant active enzyme [5]. Recombinant human MMP-2 and MMP-7 were purchased from EMD Millipore (catalog numbers PF023 and 444270, respectively; Billerica, MA), while recombinant human ADAM-10 was purchased from R & D Systems (936-AD; Minneapolis, MN). The MMP activity inhibitor GM-6001 was purchase from Tocris (catalog number 2983; Bristol, U.K.) and used at a final concentration of 2 μM. Reactions were terminated by addition of denaturing loading buffer and a 95 °C incubation (5 min) followed by freezing. Digestion products were resolved by electrophoresis on a 4–15% Tris-glycine polyacrylamide gradient gel and then transferred to a polyvinylidene difluoride (PVDF) membrane. The membrane was subsequently stained with Coomassie Blue.

Cell culture and stimulation
B35 cells
The B35 rat neuroblastoma cell line [31] was obtained from the American Type Culture Collection (Manassas, Virginia), and cultures were maintained in DMEM supplemented with glucose, penicillin/streptomycin, and 10% fetal bovine serum at 5% CO2. Cultures were at 75–80% confluence at treatment. This cell line has been extensively characterized and used in previous studies related to neural CAMs (NCAM) [32]. These cells were treated with vehicle or 500 ng/ml recombinant MMP-7 for 1 or 6 h as indicated.

Primary microglia
Mice were housed and treated in accordance with the guidelines of the Georgetown University Animal Care and Use Committee. Primary murine microglial cells were prepared from C57BL/6 P1-P3 pups as previously described [33] which results in a cell culture purity >95%. Briefly, mixed glial cultures were grown for 14–17 days from the cortices of neonatal murine pups (P1-3) in Microglial Complete Medium (Minimum Essential Medium Earle's, supplemented with 1 mM L-glutamine, 1 mM sodium pyruvate, 0.6% D-(+)-glucose, 100 μg/mL penicillin/streptomycin, 4% v/v fetal bovine serum, and 6% v/v horse serum). After 14–17 days in vitro, the microglia were isolated via rotary shaking (200 RPM; 37 °C; 5 h) and subsequently plated at a density of 1 x 10^5 cells per well (24-well plates) in 0.5 mL of Microglial Growth Media (Minimum Essential Medium Earle's, supplemented with 1 mM sodium pyruvate, 0.6% v/v D-(+)-glucose, 1 mM L-glutamine, 100 μg/mL penicillin/streptomycin, and 5% v/v fetal bovine serum) and subjected to experimentation as described below 24 h after plating. Unless otherwise noted, microglial cell cultures were stimulated with 75 nM recombinant N-cdh in MGM. This concentration was effective in preliminary dose-response experiments in which the microglia were exposed to 15, 37.5, or 75 nM recombinant N-cdh, and TNF-α levels in the conditioned media were measured by ELISA. Using an ANOVA, differences between the control and stimulated groups became significant at 75 nM (control 14.75 ± 0.65 S.E.M., 15 nM: 25.75 ± 5.15 S.E.M., 37.5 nM: 103.2 ± 31.5, and 75 nM: 350.6 ± 130.8); therefore, 75 nM was chosen for the studies presented herein. For the TNF-α ELISA experiments, microglia were treated with PBS, 75 nM of N-cdh, heat-inactivated N-cdh (85 °C, 10 min), or normal mouse IgG (0.4 μg/well) for 24 h and the conditioned media retained and assayed as described below. Microglia used for the integrin blocking experiments were pre-treated for 30 min in the presence or absence of 500 μM RGDS followed by exposure to N-cdh or PBS for 24 h. TNF-α release was quantified in the conditioned media.

Lysates and Western blot
Lysates from cultured cells were prepared via the addition of lysis buffer [50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 1% NP-40, 0.5% sodium deoxycholate, 0.2 mM phenylmethylsulfonyl fluoride (PMSF), and 1× protease inhibitor cocktail (Sigma P8340)]. The mixture was placed into a microfuge tube, sonicated for 10 s, kept on ice for 20 min, and then spun at 14,000 rpm for 15 min at 4 °C in a microcentrifuge. Supernatants were then saved and used in Western blot experiments. Western blot was performed using 40 μg of protein per lane for B35 cell lysates or 12 μg per lane for primary microglial cell lysates. Prior to analysis, samples were mixed with sample buffer containing 5% β-mercaptoethanol and boiled for 5 min at 95 °C. Electrophoresis was performed on Tris-glycine polyacrylamide gradient gels (Biorad, Hercules, CA). Following electrophoretic transfer of the protein to nitrocellulose or PVDF (Iba-1 experiments), membranes were stained with Ponceau S to ensure equal loading and transfer. Membranes were then blocked in 5% nonfat dry milk in Tris-buffered saline with 0.1% Tween (TBST) for 1 h. The blot was then probed with the indicated primary antibody, at a dilution recommended by the manufacturer (see figure legend for specific dilutions), overnight at 4 °C. After
washing the membrane three times (15 min each) in TBST, antigen-antibody complexes were incubated with the appropriate HRP-conjugated secondary antibody for 1–2 h at room temperature. The membrane was then washed again in TBST, followed by TBS and immunoreactive bands were visualized using electrochemiluminescence (Amersham/GE Healthcare Life Science; Piscataway, NJ).

ELISA
TNF-α, pro-matrix metalloproteinase-9 (MMP-9), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1) protein concentrations in cell culture supernatants were quantified using commercially available enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer’s instructions (R&D Systems; Minneapolis, MN).

Immunocytochemistry (NF-κB)
Microglia were plated on glass coverslips (1 × 10⁵ cells/cover slip; 12 mm; Deckglaser, Germany), stimulated as described, and subsequently processed for immunocytochemistry. More specifically, following treatment, cells were washed with PBS for 5 min, fixed with PBS containing 4% (w/v) paraformaldehyde and 4% (w/v) sucrose (pH 7.4) at room temperature for 15 min, permeabilized in PBS containing 0.1% (v/v) triton X-100 for 5 min, and blocked for 1 h with PBS containing 10% (v/v) goat serum. Cells were subsequently incubated overnight at 4 °C with rabbit anti-NF-κB (p65; 1:1000, Abcam; Cambridge, MA) in blocking buffer. This antibody was generated against amino acids 532-551 of the p65 subunit. Antibody/antigen complexes were visualized following incubation with Alexa Fluor® 594 conjugated goat anti-rabbit IgG secondary antibody (1:1000; Molecular Probes/Thermo Fisher Scientific; Waltham MA) in PBS containing 0.1% (v/v) triton X-100 and 1% goat serum. Cells were subsequently incubated overnight at 4 °C with rabbit anti-NF-κB (p65; 1:1000, Abcam; Cambridge, MA) in blocking buffer. This antibody was generated against amino acids 532-551 of the p65 subunit. Antibody/antigen complexes were visualized following incubation with Alexa Fluor® 594 conjugated goat anti-rabbit IgG secondary antibody (1:1000; Molecular Probes/Thermo Fisher Scientific; Waltham MA) in PBS containing 0.1% (v/v) triton X-100 and 1% goat serum. Unbound 2° antibody was removed by washing with PBS containing 0.1% (v/v) triton X-100. Cells were counterstained with 4’6-diamidino-2-phenylindole (DAPI; 13.0 ng/μL; Thermo Fisher Scientific) in PBS for 5 min followed by two washes with PBS. Coverslips were mounted with Citifluor (Ted Pella, Redding, CA) and sealed with nail polish. Cells were imaged using a Zeiss Axioskop fluorescent microscope (Carl Zeiss; Thornwood, NY). For nuclear signal quantification, images of NF-κB and DAPI were captured from five distinct, randomly selected regions of each treatment condition for 25–60 cells per treatment group. Quantification of nuclear NF-κB intensity was completed as previously described [34, 35] utilizing Image J software (National Institutes of Health; Bethesda, MD).

MyD88 homodimerization inhibition
Primary microglia were plated as described above (1 × 10⁵ cells/cover slip). Cells were subsequently pre-treated with 200 μM of control peptide or MyD88 inhibitory peptide (Imgenex; San Diego, CA) for 30 min, followed by exposure to 75 nM recombinant N-cdh for 2 h. Cells were subsequently processed for immunocytochemistry as described above, and supernatants collected for ELISA.

Statistical analysis
Data were analyzed with Graphpad Prism software using a two-tailed t test or ANOVA for comparisons of more than two groups. Significance was determined as p < 0.05.

Results
Cleavage of N-cdh by MMP-7
In previous work, we have observed increased levels of MMP-7 in association with HIV dementia [36]. MMP-7 has also been linked to neuroinflammation with multiple sclerosis and depression [37–39]. Moreover, MMP-7 inhibitors have been shown to reduce N-cdh shedding from vascular smooth muscle cells [40]. Initial experiments were therefore performed to examine cleavage of recombinant N-cdh with increasing concentrations of MMP-7. Results are shown in Fig. 1a and suggest that MMP-7 generates discreet cleavage fragments. Though the identity of precise cleavage sites cannot be inferred without sequence analysis, the presence of discreet high molecular weight bands is consistent with proteolytic cleavage that generates long portions of the ectodomain. The band at approximately 90 kDa is consistent with the described propensity for MMPs to cleave CAMs at membrane proximal sites while smaller bands are consistent with additional cleavage sites within the full N terminal domain [1, 15]. Shown in Fig. 1b, c are results from in vitro digests using MMP-2 and ADAM-10, respectively. The latter is known to stimulate ectodomain shedding of N-cdh [41] and, similar to MMP-7, it generates cleavage fragments of approximately 90 kDa (arrow). In contrast, in our experimental system, MMP-2 did not generate cleavage fragments. Shown in Fig. 1d are results from digests performed using 1.25 μg rN-cdh and 0.5 μg rMMP-7 in the presence or absence of 2 μM GM-6001, an inhibitor of MMP activity. As can be appreciated, GM-6001 inhibited MMP-7-associated cleavage of recombinant N-cdh. An equivalent amount of DMSO (3.8%), in which GM-6001 was dissolved, did not inhibit MMP-7-mediated cleavage (rN-cdh + DMSO + MMP-7).

To investigate potential MMP-mediated cleavage of membrane-tethered N-cdh and shedding from neuronal cells in particular, subsequent studies tested MMP-7 for its ability to stimulate N-cdh shedding from a neuronal cell line [31]. We used 500 ng/ml MMP-7 as MMP levels in the nanogram per milliliter range have been detected in cerebrospinal fluid samples of patients with HIV dementia. As shown in Fig. 1e, treatment of B35 neuronal cells with MMP-7 was associated with a rapid
reduction in detectable full length N-cdh immunoreactivity in cell lysates, consistent with release of ectodomain into the culture supernatant.

**Soluble N-cdh acts on primary microglial cells to stimulate nuclear translocation of NF-κB and increased levels of Iba-1 in lysates**

Ectodomain shedding of CAMs would be expected to alter trans-cellular adhesive interactions [42]. In addition, a subset of CAM C-terminal fragments (CTFs) can influence gene transcription [16, 43]. A non-mutually exclusive mechanism by which CAM shedding could substantially influence cell biology involves the potential for soluble CAMs to interact with previously unengaged cell surface receptors to stimulate intracellular signaling cascades [10, 14, 44, 45].

Microglial cells express relatively high levels of potential receptors for adhesion molecule fragments, including integrins and TLRs. Moreover, activation of this cell type has been increasingly implicated in the pathogenesis of neurodegenerative disorders including MS [29]. We therefore tested soluble N-cdh ectodomain for its ability to stimulate microglial activation as measured by increased nuclear translocation of NF-κB and expression of ionized calcium-binding adapter molecule, Iba-1, protein. As shown, soluble N-cdh stimulates a qualitative and quantitative increase in nuclear NF-κB immunoreactivity (Fig. 2a, b), as inferred by immunostaining for the p65 subunit and analysis of signal intensity. In addition, N-cdh stimulates an increase in Iba-1 levels in microglial lysates (Fig. 2c, d). As determined by densitometric analysis, the N-cdh stimulated increase in Iba-1 to GAPDH signal intensity is significant at $p < 0.05$.

**Soluble N-cdh increases release of microglial proteins including TNF-α**

Though microglial cells are heterogeneous in terms of their phenotype, recent studies suggest that populations may be relatively polarized with “classically activated” populations described as M1 cells and alternatively or
de-activated populations described as M2 [46]. Increased release of the pro-inflammatory cytokine TNF-α can follow from NF-κB signaling and is typically associated with M1 polarization, which in turn may be particularly inimical in the setting of neurodegeneration and neuro-inflammation [47]. As shown in Fig. 3a, b, release of TNF-α is significantly increased in N-cdh-stimulated microglia. In contrast, equivalent concentrations of heat-inactivated N-cdh or IgG control or PBS treatment did not have a significant effect on TNF-α release (Fig. 3a, b). Due to limitations associated with increased release of a single soluble activation marker, additional experiments were performed to assess N-cdh-dependent release of MMP-9 and MCP-1. Results are shown in Fig. 3c, d and demonstrate that N-cdh can more generally enhance release of potential inflammatory mediators.

**Pre-treatment of microglial cells with an integrin antagonist does not abrogate N-cdh-stimulated TNF-α release**

Similar to their full-length counterparts, shed CAMs can interact with cell surface receptors through homophilic and heterophilic interactions. In previous studies, we and others have observed that shed CAMs can bind to unengaged integrins to in turn stimulate changes in intracellular signaling [14, 44, 48].

Microglia express a variety of integrins including α5β1, an integrin that has been linked to both microglial activation and increased expression of the pro-inflammatory...
molecule MMP-9 [49]. This is one of several integrins that recognizes ligands with an RGD amino acid sequence [50]. We therefore tested an RGDS peptide, which blocks the activation of RGD-binding integrins, for its potential to abrogate N-cdh-stimulated TNF-α release. The microglia were pretreated for 30 min in the presence or absence of 500 μM RGDS followed by exposure to N-cdh or PBS for 24 h. TNF-α release was quantified in the conditioned media. Results, shown in Fig. 4, demonstrate that this peptide does not abrogate N-cdh-stimulated TNF-α release in our experimental system.

A peptide inhibitor of MyD88-dependent TLR signaling, abrogates N-cdh-stimulated NF-κB translocation and TNF-α release

TLRs represent a class of pattern recognition receptors (PRRs) that are highly expressed on microglia and linked to classical activation. PRRs are activated by varied exogenous ligands called pathogen-associated molecular patterns (PAMPs) which include triacyl lipopeptides, flagellin, dsDNA, ssRNA, and bacterial lipopolysaccharides [51]. More recently, these same TLRs have been shown to bind endogenous ligands, referred to as damage-associated molecular patterns (DAMPs), molecules that are typically exposed or increased with tissue injury [19, 20, 25, 52]. Since soluble CAM levels are

![Fig. 3](image_url) Soluble N-cdh increases microglial cell release of immune modulators including TNF-α. Supernatants from control or N-cdh-stimulated (75 nM, 18 h) microglia were tested by ELISA for TNF-α. Results from an experiment performed in triplicate with vehicle, N-cdh, or an equivalent amount of heat-inactivated protein (HI N-cdh; 95 °C for 30 min) are shown in (a) while results from a quadruplicate experiment with vehicle and IgG controls are shown in (b). The difference between control and N-cdh is significant at *p < 0.05 for both experiments. The difference between control groups is not significant for either. N.D. = not detectable. In (c and d), we show results from a similar experiment performed in triplicate with vehicle or N-cdh (75 nM, 18 h). In this experiment, supernatant levels of pro-MMP-9 or MCP-1 were evaluated as indicated, and a significant increase in both was observed.

![Fig. 4](image_url) Pre-treatment of microglial cells with an integrin antagonist does not abrogate N-cdh-stimulated TNF-α release. An RGDS peptide was tested for its potential to attenuate N-cdh-stimulated TNF-α release from primary microglial cells. Supernatants from vehicle control (PBS), RGDS pre-treated (500 μM, 30 min pretreatment), and N-cdh (75 nM) with or without RGDS pre-treatment (500 μM, 30 min pretreatment) were collected 18 h later and analyzed by ELISA. The mean and standard error are shown in Fig. 4, and difference between pre-treated and non pre-treated N-cdh groups was not significant (N.S.). Supernatant from both groups that received N-cdh had significantly higher levels of TNF-α compared to control and RGDS alone (*n = 4 per group; *p < 0.05).
increased with tissue injury [53–55], and have regions homologous to matrix fragments that have been implicated in TLR signaling [20], CAM fragments could represent a class of DAMPs. We therefore examined a peptide inhibitor of MyD88 homodimerization, an event necessary for signaling through a subset of TLRs, for its potential to abrogate N-cdh-stimulated NF-κB translocation and TNF-α release. Because NF-κB translocation occurs relatively quickly, in these experiments, we examined changes in both NF-κB and TNF-α at 2 h, a timepoint that we previously demonstrated to be appropriate for both p65 nuclear translocation and TNF-α release [56]. As shown in Fig. 5, inhibition of MyD88 homodimerization reduced N-cdh-stimulated increases in both endpoint measures. These data suggest that TLR signaling may contribute to N-cdh-mediated microglial activation.

**Discussion**

MMPs represent a family of enzymes initially named for their potential to remodel extracellular matrix [57, 58]. Expression and/or release of select MMPs is increased in the background of neuroinflammation [59]. Published studies have demonstrated that MMP activity can cleave BBB tight junction and basement membrane components to facilitate the CNS ingress of specific leukocyte subpopulations [7]. Recently published works posit that MMPs can produce DAMPs through their potential to process large ECM proteins such as hyaluron [60, 61]. Less well studied is the question of whether increased MMP activity contributes to disease pathogenesis through excessive CAM cleavage.

CAMs represent an important target for cell-associated and cell-secreted MMPs. In vitro and in vivo studies suggest that metalloproteinase activity is concentrated at the cell surface [62, 63] and emerging evidence links CAM shedding to important physiological and pathological endpoints [48, 64]. CAM integrity is important to synaptic stability, axon-myelin interactions, and reactive synaptopathogenesis following injury [13, 42]. In addition, shedding of specific CAMs is linked to the generation of intracellular domains that influence gene transcription [43]. For example, N-cdh shedding leads to the generation of a CTF that inhibits CREB-dependent gene transcription [16]. A third and non-mutually exclusive consequence of CAM shedding, and one that is increasingly appreciated in recent studies, is the possibility that shed NTFs are themselves potent effectors of diverse normal and pathological processes. These fragments are relatively stable, as

![Fig. 5](image-url)
suggested by studies in which varied CAM NTFs can be detected in cerebrospinal fluid samples from normal and/or diseased individuals [53–55, 65]. Similar to their full-length counterparts, shed CAMs can likely interact with cell surface receptors through homophilic and heterophilic interactions [14, 66]. This is supported by published work in which soluble ICAM-5 can interact with neuronal surface molecules including full-length ICAM-5 and β1 integrins [14, 15].

TLRs represent another class of cell surface molecules that might be engaged by soluble CAMs as these PRRs are activated by injury-associated molecular patterns (DAMPs) [19, 20, 25, 52]. Soluble CAM levels may be increased with brain injury [53–55], and these molecules have regions homologous to matrix components that have been implicated in TLR signaling [20]. CAM fragments could therefore represent a class of DAMPs.

In the present study, we show that MMP-7 can cleave recombinant N-cdh. Similar to ADAM-10, which has been demonstrated to stimulate ectodomain shedding of N-cdh [41, 67, 68], MMP-7 generates a fragment of approximately 90 kDa. Though sequencing studies would be confirmatory, given that recombinant N-cdh contains the entire ectodomain and is of similar molecular weight to native protein, this result is consistent with the described ability of MMPs to cleave CAMs at a membrane proximal position. Ectodomain shedding is further supported by loss of N-terminal N-cdh immunoreactivity in lysates from MMP-7-treated neural cells. While our focus was on MMP-7, due to overlapping substrate specificity, we acknowledge that additional MMPs might stimulate N-cdh shedding in select settings. A subset of family members is expressed in the brain and, like MMP-7, may be upregulated with inflammation [69].

Herein, we also show that soluble N-cdh can stimulate microglial activation as demonstrated by varied endpoints including increased expression of Ilbα1, nuclear localization of NF-κB, and release of TNF-α. Moreover, we suggest that TLR signaling in particular can contribute to N-cdh-stimulated microglial activation, since endpoint measures are significantly reduced by an inhibitor of MyD88 signaling. Though inhibition is incomplete, it should be noted that blocking MyD88 signaling with peptides or siRNA typically has partial effects in terms of attenuating TLR signaling [52, 70, 71]. Changes in overall TNF-α levels are of interest, as is increased nuclear localization of a transcription factor linked to inducible TNF-α expression. Importantly, however, while both likely reflect microglial activation, the two are not necessarily causally related. Transcription factors additional to NF-κB are important to TNF-α. Moreover, TNF-α can be released from preformed stores [72]. Of additional note, N-cdh also increased expression and/or release of additional proteins that may be regulated in an NF-κB-dependent manner: MCP-1 and MMP-9 [73, 74].

Soluble N-cdh-dependent microglial activation is of interest. Classical microglial activation has been implicated as a mediator of hippocampal and synaptic injury in varied disease models. A recent study, which focused on hippocampal dysfunction in a mouse model of multiple sclerosis, noted that a loss of inhibitory interneurons occurred with associated microglial activation and a relative lack of infiltrating blood-borne immune cells [29]. Recent work has also shown that MMP-7 is increased with major depression [75], a condition that is increasingly associated with microglial activation [76]. That N-cdh stimulated an increase in TNF-α release is of interest in that this cytokine is typically associated with classical or pro-inflammatory M1 polarization. Though M1 as opposed to immunoregulatory or anti-inflammatory M2 polarity is a complex distinction, and characteristics of each are not mutually exclusive, it is worth noting that the M1 phenotype may be inimical to neuronal repair [47].

The potential for an MMP-generated fragment to activate microglia also provides a potential mechanistic link for studies that have shown reduced microglial activation in the background of MMP inhibition. For example, tetracycline and tetracycline derivatives can directly inhibit the activity of already formed MMPs via chelation of the active site zinc atom [77]. Tetracycline derivatives are now used in varied disease models to reduce microglial activation. It is thus tempting to speculate that reduced microglial activation follows, at least in part, from reduced levels of microglial-activating CAM fragments.

Herein, we also show that specific cell surface receptors may be important to soluble N-cdh-dependent microglial activation. As compared to other resident cells of the CNS, microglia express high levels of two receptor classes that have been linked to their activation, integrins and TLRs [78, 79]. Our studies suggest a role for the latter in N-cdh-dependent effects. We cannot, however, rule out an effect for other cell surface molecules including CAM-binding fibroblast growth factor (FGF) receptors [80]. In addition, though an antagonist for RGD-binding integrins did not block N-cdh-stimulated TNF-α release in our system, it would be premature to exclude a role for integrins in MMP-dependent microglial activation. For example, N-cdh could interact with non-RGD-binding integrins that are linked to microglial activation. Moreover, damage-associated MMPs might stimulate shedding of additional CAMs, such as ICAM-5, whose NTFs might engage RGD and non-RGD-binding microglial integrins [78, 81].

While pathological shedding of CAMs may stimulate widespread and injurious microglial activation, it is important to consider that regulated shedding might be important to physiological microglial functions. For
example, since MMPs can be released in a neuronal activity dependent manner, it is tempting to speculate that regulated CAM-dependent microglial activation could potentially contribute to physiological synaptic pruning [82].

Conclusions
In summary, our data suggest that N-cdh shedding can be stimulated by MMP-7 and that soluble N-cdh represents a novel effector of classical microglial activation. Future in vivo studies to better understand the consequences of disease-associated CAM shedding are warranted.

Abbreviations
CAM: Cell adhesion molecule; CTF: C-terminal fragment; DAMP: Damage-associated molecular pattern; ELISA: Enzyme-linked immunosorbent assay; FGF: Fibroblast growth factor; Iba-1: Ionized calcium binding adaptor molecule-1; ICAM: Intercellular adhesion molecule; ICAM-5: Intercellular adhesion molecule-5; Iba-1: Ionized calcium binding adaptor molecule-1; K186: Polyvinylidene difluoride; TLR: Toll-like receptor; TNF-α: Tumor necrosis factor-α

Acknowledgements
Not applicable.

Funding
We would like to acknowledge funding from the Von Mutsh professorship for neurological diseases, the National Multiple Sclerosis Society (RG4031AZ/1), and the National Institutes of Health (MH096822, NS083410) and T32 NS041231 to PLB.

Availability of data and materials
All raw data used in this manuscript are available on request.

Authors’ contributions
SD, PLB, TA, and AE performed the cell culture and Western blots. SD performed the immunostaining. KC, SD, PLB, and KMZ performed data analysis. KC and KMZ designed experiments, and KC, SD, PLB, and KMZ contributed to the writing and editing of the manuscript. All authors read and approved the manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval
The animal care and use committee at Georgetown University School of Medicine approved all studies. The IACUC protocol identification number is 15-048 (previously 12-042) and 13-057 (now 2016-1154).

Author details
1Department of Neuroscience, Georgetown University School of Medicine, Washington, D.C., USA. 2Jagiellonian Center of Innovation, Krakow, Poland.

Received: 25 March 2016 Accepted: 27 February 2017
Published online: 17 March 2017

References
1. Conant K, Allen M, Lim ST. Activity dependent CAM cleavage and neurotransmission. Front Cell Neurosci. 2015;9:305.
2. Yang Y, Rosenberg GA. Matrix metalloproteinases as therapeutic targets for stroke. Brain Res. 2015;1623:30–8.
3. Sidhu H, Dansie LE, Hickmott PW, Ethell DW, Ethell IM. Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model. J Neurosci. 2014;34:9867–79.
4. Valadare B, Salaman A, Kaczmarek L, MMP-9 in Translating From Molecule to Brain Physiology, Pathology and Therapy. J Neurochem. 2016;139 Suppl 291–114.
5. Milward E, Kim KJ, Szklarczyk A, Nguyen T, Melli G, Nakay M, Deshpande D, Fitzsimmons C, Hoke A, Kerr D, et al. Cleavage of myelin associated glycoprotein by matrix metalloproteinases. J Neuroimmunol. 2008;193:140–8.
6. Sinyavsky I, Savinov AY, Cieplak P, Ratnikov BI, Mostamedchahoki K, Smith JW, Strongin AY. Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis. PLoS ONE. 2009;4:e4952.
7. Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, Fini ME, Lo EH. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurolsci. 2001;21:7724–32.
8. Rosell A, Lo EH. Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol. 2008;8:82–9.
9. Gurney KJ, Estrada EY, Rosenberg GA. Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiol Dis. 2006;23:87–96.
10. Conant K, Lim ST, Randall B, Maguire-Zeiss KA. Matrix metalloproteinase dependent cleavage of cell adhesion molecules in the pathogenesis of CNS dysfunction with HIV and methamphetamine. Curr HIV Res. 2012;10:384–91.
11. Huntley GW. Synaptic circuit remodelling by matrix metalloproteinases in health and disease. Nat Rev Neurosci. 2012;13:743–57.
12. Caremini S, Montag D, Cremers H, Schachner M, Martin R. Absence of the myelin-associated glycoprotein (MAG) and the neural cell adhesion molecule (N-CAM) interferes with the maintenance, but not with the formation of peripheral myelin. Cell Tissue Res. 1997;287:3–9.
13. Warren KM, Reeves TM, Phillips LL. MT5-MMP, ADAM-10, and N-cadherin act in concert to facilitate synaptic reorganization after traumatic brain injury. J Neurotrauma. 2012;29:1922–40.
14. Lonskaya I, Partridge J, Lalchandani RR, Chung A, Lee T, Vinieri S, Hoe HS, Lim ST, Conant K. Soluble ICAM-5, a protein of activity dependent proteolysis, increases mTSPC frequency and dendritic expression of GluA1. PLoS ONE. 2013;8:e69136.
15. Tian L, Stefanidakis M, Ning L, Van Lint P, Nymann-Huttunen H, Libert C, Itohara S, Mishina M, Rauhala V, Gahmberg CG. Activation of NMDA receptors promotes dendritic spine development through MMP-mediated ICAM-5 cleavage. J Cell Biol. 2007;178:687–700.
16. Marambaud P, Wen PH, Dutt A, Shioi J, Takashima A, Siman R, Robakis N. A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell. 2003;114:635–45.
17. Massaro AR, De Passalis D, Carnevale A, Carbone G. The neural cell adhesion molecule (N-CAM) present in the cerebrospinal fluid of multiple sclerosis patients is unsialylated. Eur Rev Med Pharmacol Sci. 2009;13:397–9.
18. Strekalova H, Buhmann C, Kleene R, Eggers C, Saffell J, Hemperly J, Weiller C, Muller-Thomsen T, Schachner M. Elevated levels of neural recognition molecule L1 in the cerebrospinal fluid of patients with Alzheimer disease and other dementia syndromes. Neurobiol Aging. 2006;27:114–21.
19. Erridge C. Endogenous ligands of TLR2 and TLR4: agonists or antagonists? J Leukoc Biol. 2010;87:989–99.
20. Janssens S, Beyer R. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev. 2003;16:537–66.
21. Valanne S, Wang JH, Ramet M. The Drosophila Toll signaling pathway. J Neurotrauma. 2011;28:649–56.
22. Zhang G, Ghosh S. Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest. 2001;107:13–9.
23. Rubartelli A. DAMP-mediated activation of NLPR3-inflammasome in brain sterile inflammation: the fine line between healing and neurodegeneration. Front Immunol. 2014;5:99.
24. Savage CD, Lopez-Castejon G, Denes A, Brough D. NLRC3-inflammasome activating DAMPs stimulate an inflammatory response in glia in the absence of priming which contributes to brain inflammation after injury. Front Immunol. 2012;3:288.
25. Racke MK, Drew PD. Toll-like receptors in multiple sclerosis. Curr Top Microbiol Immunol. 2009;336:155–8.
26. Bronson CF, Bonstein MB, Yost G, Mostamedchahoki K, Smith JW, Strongin AY. The effects of macrophage depletion on the clinical and pathologic expression of experimental allergic encephalomyelitis. J Neuroimmunol. 1981;12:614–20.
27. Hultinga I, van Rooijen N, de Groot CJ, Uitdehaag BM, Dijkstra CD. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J Exp Med. 1990;172:1025–33.
28. Lucchini CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, Bruck W, Parisi JE, Scheithauer BW, Giannini C, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011;365:2188–97.

29. Ziehn MO, Avedissian AA, Tiwari-Woodruff S, Voskuhl RR. Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune encephalomyelitis. EAE Lab Invest. 2010;90:774–86.

30. Tavazzi E, Morrison D, Sullivan P, Moroello S, Fischer T. Brain inflammation is a common feature of HIV-infected patients without HIV encephalitis or productive brain infection. Curr HIV Res. 2014;12:97–110.

31. Schubert D, Heinemann S, Carlisle W, Tarikas H, Kimes B, Patrick J, Steinbach LH, Brandt BL. Clonal cell lines from the rat central nervous system. Nature. 1997;424:204–7.

32. Diestel S, Hinkle CL, Schnitz B, Maness PF. NCAM140 stimulates integrin-dependent cell migration by ectodomain shedding. J Neurochem. 2005;95:1777–84.

33. Daniele SG, Edwards AA, Maguire-Zeiss KA. Isolation of cortical microglia with preserved immunophenotype and functionality from murine neocortices. J Vis Exp. 2014;83:e51005.

34. Noursadeghi M, Tsang J, Hausstein T, Miller RF, Chain BM, Katz DR. Quantitative imaging assay for NF-kappaB nuclear translocation in primary human macrophages. J Immunol Methods. 2006;319:194–200.

35. Fuseler JW, Merril DD, Rogers JA, Grisman MB, Wolf RE. Analysis and quantitation of NF-kappaB nuclear translocation in tumor necrosis factor alpha (TNF-alpha) activated vascular endothelial cells. Microsc Microanal. 2006;12:69–76.

36. Conant K, McArthur JC, Griffin DE, Sjulson L, Wahl LM, Irani DN. Cerebrospinal fluid levels of MMP-2, -7, and -9 are elevated in association with human immunodeficiency virus dementia. Ann Neurol. 1999;46:391–8.

37. Kanesaka T, Mori M, Hattori T, Oki T, Kuwabara S. Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006;77:185–8.

38. Anthony DC, Miller KM, Fearn S, Townsend MJ, Opdenacker G, Wells GM, Champlin JM, Chandler S, Gearing AJ, Perry VH. Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS. J Neuromucronol. 1998;86:72–72.

39. Cossins JA, Clements JM, Chandler S, Gearing AJ, Perry VH. Matrix metalloproteinase expression and pathology of the nervous system. Nat Rev Neurosci. 2001;2:502–3.

40. Hinkle CL, Diestel S, Lieberman J, Maness PF. Metalloprotease-induced cleavage of N-cadherin and promotes smooth muscle cell apoptosis. Cardiovasc Res. 2010;87:137–46.

41. Reiss K, Maretzky T, Ludwig A, Tousseyn T, de Strooper B, Hartmann D, Balschun D, Willem M, et al. Postnatal disruption of the disintegrin/metalloproteinase ADAM10 in brain causes epileptic seizures, learning deficits, altered spine morphology, and defective synaptic function. J Neurosci. 2013;33:12015–28.

42. Benson DL, Schnapp LM, Shapiro L, Huntley GW. Making memories stick: the alpha(2)beta(1) integrin upon release from keratinocytes migrating on type I collagen. J Biol Chem. 2001;276:29368–74.

43. van der Kooij MA, Fantin M, Reijmak E, Gross J, Zanotti O, Fournier C, Ganguly K, Kalita K, Kaczmarek L, Sandi C. Role for MMP-9 in stress-induced downregulation of nectin-3 in hippocampal CA1 and associated behavioural alterations. Nat Commun. 2014;5:4995.

44. Avetov MP, Uzen N, Thatcher L, Ladenheim B, Zhang P, VanderPutten DM, Conant K, Herman MM, van Kemenen DP, Sedvall G, et al. Characterization of human cleaved N-CAM and association with schizophrenia. Exp Neurol. 2001;172:29–46.

45. Gahmberg CG, Tian L, Ning L, Nyman-Huttunen H. ICAM-5—a novel two-faceted adhesion molecule in the mammalian brain. Immunol Lett. 2008;117:131–5.

46. Prox J, Berreuthker C, Altmeppe H, Gendel J, Glatzel M, Dhooge R, Srobona S, Ahmed T, Balaschun D, Willem M, et al. Postnatal disruption of the disintegrin/metalloproteinase ADAM10 in brain causes epileptic seizures, learning deficits, altered spine morphology, and defective synaptic function. J Neurosci. 2013;33:12015–28. 12928a.

47. Uemura K, Kihara T, Kuzuya A, Okawa K, Nishimoto T, Ninomiya H, Sugimoto K, Hinoshita A, Shimojima S. Characterization of sequential N-cadherin cleavage by ADAM10 and PS1. Neurosci Lett. 2006;402:278–83.

48. Yong VW, Krebski CA, Forsyth PA, Bell R, Barlow D, Bournseth DR. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 1998;21:75–80.

49. Gaudet AD, Popovich PG. Extracellular matrix regulation of inflammation in the healthy and injured spinal cord. Exp Neurol. 2014;258:24–34.

50. Kigerl KA, de Rivero Vaccari JP, Dietrich WD, Popovich PG, Keane RW. Pattern recognition receptors and central nervous system repair. Exp Neurol. 2014;258:5–18.

51. Jiang T, Olivero ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging with means of protolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A. 2004;101:17867–72.

52. Dumin JA, Dickeson SK, Stricker TP, Bhattacharyya-Pakrasi M, Roby JD, Santoro SA, Parks WC. Pro-collagenase-1 (matrix metalloproteinase-1) binds the alpha2beta1 integrin upon release from keratinocytes migrating on type I collagen. J Biol Chem. 2001;276:3628–74.

53. Yan W, Fan WN, Chen CJ, Wu YQ, Fan ZY, Chen JQ, Chen HM. IL-10 receptor blockade reduces the pathological effects of herpes simplex virus infection on the central nervous system. J Neuroinflamm. 2017;14:86.

54. Lindsberg PJ, Launes J, Tian L, Valmia H, Subramanian V, Sreen J, Hokkanen L, Hyyppa T, Carpen O, Gahmberg CG. Release of soluble ICAM-5, a neuronal adhesion molecule, in acute encephalitis. Neurology. 2002;58:466–71.

55. Guo H, Tong N, Turner T, Epstein LG, McDermott MP, Kilgannon P, Gelbard HA. Release of the neuronal glycoprotein ICAM-5 in serum after hypoxic-ischemic injury. Ann Neurol. 2000;48:590–602.

56. Daniele SG, Beraud D, Davenport C, Cheng K, Yin H, Maguire-Zeiss KA. Activation of MyD88-dependent TLR1/2 signaling by misfolded alpha-synuclein, a protein linked to neurodegenerative disorders. Sci Signal. 2015;8:ra45.

57. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they’re not just for matrix anymore! Curr Opin Cell Biol. 2015;83:76–76.
75. Frye MA, Nassan M, Jenkins GD, Kung S, Veldic M, Palmer BA, Feeder SE, Tye SJ, Choi DS, Biernacka JM. Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders. Transl Psychiatry. 2015;5:e689.

76. Rial D, Lemos C, Pinheiro H, Duarte JM, Goncalves FQ, Real JI, Prediger RD, Goncalves N, Gomes CA, Caras PM, et al. Depression as a glial-based synaptic dysfunction. Front Cell Neurosci. 2015;9:521.

77. Duivenvoorden WC, Hirte HW, Singh G. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells. Invasion Metastasis. 1997;17:312–22.

78. Milner R, Campbell IL. The integrin family of cell adhesion molecules has multiple functions within the CNS. J Neurosci Res. 2002;69:286–91.

79. Lee H, Lee S, Cho IH, Lee SJ. Toll-like receptors: sensor molecules for detecting damage to the nervous system. Curr Protein Pept Sci. 2013;14:33–42.

80. Utton MA, Eickholt B, Howell FV, Wallis J, Doherty P. Soluble N-cadherin stimulates fibroblast growth factor receptor dependent neurite outgrowth and N-cadherin and the fibroblast growth factor receptor co-cluster in cells. J Neurochem. 2001;76:1421–30.

81. Mizuno T, Yoshihara Y, Kagamiyama H, Ohsawa K, Imai Y, Koshaka S, Mori K. Neuronal adhesion molecule telencephalin induces rapid cell spreading of microglia. Brain Res. 1999;849:58–66.

82. Tremblay ME, Lowery RL, Majewska AK. Microglial interactions with synapses are modulated by visual experience. PLoS Biol. 2010;8:e1000527.